President Donald Trump has nominated Dr. Casey Means, a physician and health tech entrepreneur, as the next U.S. Surgeon General. The announcement, made Wednesday, highlights Means' alignment with Health Secretary Robert F. Kennedy Jr.’s "Make America Healthy Again" initiative.
Dr. Means, 37, co-founded the health technology company Levels, which uses data from continuous glucose monitors to help users understand how their food choices affect metabolic health. She is a strong advocate for using personalized data to drive healthier lifestyles and is widely seen as a rising voice in the preventive health and biohacking movement.
Her brother, Calley Means, was recently appointed as a White House adviser, focusing on food policy reform and addressing corporate influence on national health trends. Together, the Means siblings have been vocal supporters of reshaping American health through nutrition-focused and tech-driven approaches.
Dr. Means will replace Trump’s previous nominee, Dr. Janette Nesheiwat, who the president announced will now serve in a different senior role within the Department of Health and Human Services alongside Secretary Kennedy.
As Surgeon General, Dr. Means would become the nation’s leading spokesperson on public health, responsible for delivering science-based guidance on disease prevention, wellness, and reducing chronic illness. Her nomination is expected to energize health reform advocates who support lifestyle medicine and digital health innovation.
Trump’s pick signals a continued shift toward preventive care and a broader embrace of alternative health strategies that prioritize nutrition, metabolic awareness, and data-driven wellness tools. The nomination must still be confirmed by the Senate.


New York Legalizes Medical Aid in Dying for Terminally Ill Patients
China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Marco Rubio Steps Down as Acting U.S. Archivist Amid Federal Law Limits
TrumpRx.gov Highlights GLP-1 Drug Discounts but Offers Limited Savings for Most Americans
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s
Trump Says “Very Good Talks” Underway on Russia-Ukraine War as Peace Efforts Continue
U.S. to Begin Paying UN Dues as Financial Crisis Spurs Push for Reforms
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market
UAE Plans Temporary Housing Complex for Displaced Palestinians in Southern Gaza
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Trump Signs “America First Arms Transfer Strategy” to Prioritize U.S. Weapons Sales
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 



